drugset / Trial / NCT01042392

Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients

NCT01042392

Phase 4 Completed 506 enrolled Novartis
RandomizedParallel-groupTriple-blindTreatment

Summary

This prospective multicenter, double blind study will evaluate the efficacy and safety of aliskiren versus ramipril in patients with moderate systolic essential hypertension.

Timeline

Start
2009-11
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 150 mg
Subject Aliskiren Small molecule 300 mg
Comparator Ramipril Small molecule 5 mg
Comparator Ramipril Small molecule 10 mg